The DROP-AD project shows that measuring phosphorylated tau 217 (p-tau217) in dried fingerstick plasma spots identifies Alzheimer's disease almost as well as venous blood.[1] Capillary DPS p-tau217 shows a strong correlation with venous plasma p-tau217 across all cohorts (rs=0.74, 95% CI: 0.68–0.79; p <0.001).[1] This biomarker is significantly associated with MMSE scores (r=−0.37; p <0.0001) and age (r=0.33; p <0.0001), similar to venous plasma.[1] In individuals with Alzheimer's disease pathology, p-tau217 is significantly increased in DPS by +198% with a discriminant accuracy of 0.863 (95% CI: 0.81–0.92).[1] Strong correlations were also found for NfL (r=0.83, 95% CI: 0.74–0.89) and GFAP (r=0.773, 95% CI: 0.71–0.82) between capillary DPS and venous plasma.[1] In a subgroup of 31 participants with Down syndrome, capillary and venous blood biomarker levels were significantly correlated (GFAP: r=0.629, p-tau217: r=0.875).[1] This approach simplifies sample collection and increases the availability of biomarkers for population screening and research.[1]